INDIA ORAL SOLID DOSAGE PHARMACEUTICAL FORMULATION MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026 - 2033)

India Oral Solid Dosage Pharmaceutical Formulation Market Size and Forecast – 2026 To 2033

The India oral solid dosage pharmaceutical formulation market is expected to grow from USD 16,863.7 Mn in 2026 to USD 39,316.8 Mn by 2033, registering a compound annual growth rate (CAGR) of 12.9% from 2026 to 2033. The India oral solid dosage pharmaceutical formulation market is poised for significant expansion, fueled by the government's Production Linked Incentive (PLI) Scheme, which is strengthening domestic pharmaceutical manufacturing and encouraging investments in high-value formulations, including complex generics.

According to the Ministry of Chemicals & Fertilizers, as of December 2025, the Production Linked Incentive (PLI) Scheme for pharmaceuticals had attracted cumulative investments of approximately USD 4.82 billion (INR 41,943 crore), significantly exceeding the committed investment target of USD 1.99 billion (INR 17,275 crore), reinforcing India's manufacturing ecosystem for oral solid dosage formulations

Key Takeaways of the India Oral Solid Dosage Pharmaceutical Formulation Market

• Tablets are projected to hold a market share of 66.8% of the India oral solid dosage pharmaceutical formulation market share in 2026, making it the dominant dosage form segment, owing to their manufacturing efficiency, dosage precision, and widespread use across therapeutic areas. For instance, under the Government of India's Revised Schedule M (G.S.R. 922(E)), the Central Drugs Standard Control Organization (CDSCO) strengthened GMP requirements for tablet manufacturing by introducing enhanced quality systems, process validation, equipment qualification, and risk management standards to align Indian pharmaceutical manufacturing with global GMP practices
• Anticoagulants are projected to hold 29.1% of the India oral solid dosage pharmaceutical formulation market share in 2026, making it the dominant drug class segment, driven by increasing cardiovascular disease burden and greater access to quality-assured oral medicines. For instance, anticoagulant tablets marketed in India are required to comply with CDSCO approval requirements and the strengthened GMP provisions under Revised Schedule M, reinforcing manufacturing quality, process validation, and lifecycle quality management for oral solid dosage products.
• Capsule is projected to hold 23.2% of the India oral solid dosage pharmaceutical formulation market share in 2026, making it the dominant application segment, owing to their versatility, patient compliance, and suitability for modified-release and combination therapies. For instance, the Revised Schedule M notified by the Government of India includes dedicated GMP requirements for capsule manufacturing facilities, emphasizing equipment qualification, contamination control, documentation, and pharmaceutical quality systems to strengthen manufacturing standards for capsule formulations.

Segmental Insights

To learn more about this report, Request Free Sample

Why Do Tablets Dominate the India Oral Solid Dosage Pharmaceutical Formulation Market?

Tablets are projected to hold a market share of 66.8% in 2026, attributed to economical production cost, accurate dosing, stability and easier mass production. Moreover, tablets are favored in the treatment of chronic diseases and can readily assist technologies for fixed dose combinations and controlled release preparations. For instance, in January 2026 Indian Pharmacopoeia Commission (IPC) published the 10th Edition of Indian Pharmacopoeia (IP) 2026 to revise official quality parameters, and monographs of drug products including tablet dosage forms, thereby strengthening quality assurance and regulatory harmonization for oral solid dosage formulations manufactured in India.

Why Do Anticoagulants Represent the Largest Drug Class Segment in the India Oral Solid Dosage Pharmaceutical Formulation Market?

To learn more about this report, Request Free Sample

Anticoagulants are projected to hold 29.1% of the market share in 2026, owing to growing incidences of chronic heart diseases, stroke, atrial fibrillation and deep vein thrombosis, necessitating long-term treatment using an oral anticoagulant medication. Higher prevalence of anticoagulant, growing availability of care for chronic disease management and increasing inclination towards orally delivered therapies will boost the market demand. For instance, the Ministry of Health & Family Welfare reinforces the prevention and long-term management of cardiovascular disease through the National Programme for Prevention and Control of Non-Communicable Diseases (NP-NCD) by establishing priority diagnosis and management for hypertension, encouraging sustained demand for oral anticoagulant drugs.

Cardiovascular Diseases Segment Dominates the India Oral Solid Dosage Pharmaceutical Formulation Market

Cardiovascular diseases segment is expected to hold 23.2% of the India oral solid dosage pharmaceutical formulation market share in 2026, due to the growing incidence of hypertension, coronary artery disease and heart failure which warrant lifelong pharmacotherapy in the form of tablets and capsules. The demand of oral solid dose formulations is growing due to easy availability of low priced cardiovascular generic medicines and access to long duration therapy. For instance, as of December 2025, the Department of Pharmaceuticals informed that about 17,990 Jan Aushadhi Kendras have been opened across the country under the Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) offering medicines across broad therapy areas such as cardiovascular, enhancing accessibility to oral long-term cardiovascular drugs. (Source: Press Information Bureau)

Current Events and their Impact

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

India Oral Solid Dosage Pharmaceutical Formulation Market Dynamics

To learn more about this report, Request Free Sample

Market Drivers

• Increasing demand for generic oral solid dosage formulations in domestic and export markets: The increasing demand for affordable generic oral solid dosage formulations is driving the India oral solid dosage pharmaceutical formulation market, supported by rising global demand for cost-effective therapies and India's robust manufacturing capabilities. For instance, the Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers, reported that India supplies nearly 20% of the world's generic medicines by volume, with pharmaceutical exports reaching approximately USD 30.5 billion in FY 2024–25. This reinforces India's position as a leading global hub for manufacturing and exporting generic oral solid dosage formulations.
• Rising prevalence of chronic diseases driving long-term oral medication use: The rising prevalence of chronic diseases is driving sustained demand for long-term oral medication, supporting growth in the India oral solid dosage pharmaceutical formulation market. Increasing cases of diabetes, cardiovascular diseases, hypertension, and cancer are boosting the consumption of tablets and capsules for long-term disease management. For instance, the Indian Council of Medical Research (ICMR) reported that India had approximately 101 million people living with diabetes and 136 million with prediabetes in 2023, highlighting the growing need for long-term oral pharmacotherapy.
• Increasing regulatory approvals from global health authorities: The increasing number of regulatory approvals from global health authorities is driving the India Oral Solid Dosage Pharmaceutical Formulation Market by enhancing the credibility of Indian manufacturers and expanding access to regulated export markets. For instance, the Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers, reported that India has the highest number of U.S. FDA-compliant pharmaceutical manufacturing plants outside the United States, strengthening the country's position as a global supplier of high-quality oral solid dosage formulations.

Emerging Trends

• Growing Adoption of Digital and Smart Manufacturing Technologies: Indian pharmaceutical manufacturers are increasingly integrating Industry 4.0 technologies, including artificial intelligence (AI), automation, digital twins, and real-time process monitoring, into oral solid dosage production. These technologies enhance manufacturing efficiency, improve quality assurance, and support regulatory compliance through data-driven operations.
• Increasing Shift Toward Patient-Centric Oral Solid Dosage Formulations: Manufacturers are focusing on developing patient-friendly dosage forms, including orally disintegrating tablets (ODTs), chewable tablets, mini-tablets, bilayer tablets, and fixed-dose combinations to improve treatment adherence, especially among pediatric, geriatric, and dysphagic patients.
• Rising Adoption of Sustainable and Green Pharmaceutical Manufacturing: Oral solid dosage manufacturers are increasingly investing in energy-efficient production processes, solvent reduction technologies, water conservation initiatives, and eco-friendly packaging to meet global Environmental, Social, and Governance (ESG) goals and customer sustainability expectations while improving operational efficiency.

Major Oral Solid Dosage Forms and Their Clinical Applications

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

How is the growing demand for high-potency oral solid dosage formulations and modified-release products creating new growth opportunities in the India oral solid dosage pharmaceutical formulation market?

India’s shifting perception towards oral medications and increasing need for sophisticated oral delivery methods are spurring growth of modified release and high-potency oral solid dosage formulators in the country Modified release formulation reduces the frequency of administration for better compliance and enhance patient's compliance. Also, the ability of these dosage form formulations to deliver accurate doses of highly potent APIs for managing complex chronic conditions offers potential therapeutic advantage and enhance their demand and market opportunities in both domestic and international markets. For instance, Central Drugs Standard Control Organisation (CDSCO) defines a clear regulatory trajectory to support development and commercialization of innovative oral solid formulations including modified-release dosage forms, new dosage forms, and additional strengths, which helps in the development and commercialization of innovative oral solid dosage formulations.

Market Players, Key Development, and Competitive Landscape

To learn more about this report, Request Free Sample

Key Developments

• In February 2026, DFE Pharma launched its Continuous Manufacturing (CM) Platform in collaboration with Gericke to accelerate oral solid dosage formulation development and manufacturing. The platform integrates CM-ready excipients, advanced powder processing, and data-driven process optimization to support faster product development, scale-up, and lifecycle management. The initiative is expected to enhance manufacturing efficiency and promote the adoption of continuous manufacturing technologies in oral solid dosage production.
• In February 2026, Piramal Pharma Solutions introduced Tablet-in-Capsule (TiC) manufacturing capabilities at its facilities in Ahmedabad and Pithampur, India, expanding its oral solid dosage CDMO portfolio. The technology enables multiple tablets with different release profiles to be incorporated into a single capsule, supporting the development of complex combination therapies and patient-centric oral formulations while strengthening India's advanced pharmaceutical manufacturing capabilities.

Competitive Landscape

The India oral solid dosage pharmaceutical formulation market is moderately consolidated, with leading pharmaceutical companies competing through advanced formulation technologies, manufacturing scale, regulatory compliance, and global market expansion. Market participants are increasingly investing in modified-release and high-potency oral solid dosage formulations, continuous manufacturing, digital manufacturing technologies, and quality-by-design (QbD) approaches to strengthen product portfolios. Expansion of U.S. FDA-, EU GMP-, and WHO-GMP-compliant manufacturing facilities, coupled with investments in complex generics and CDMO capabilities, continues to serve as a key competitive differentiator. Key focus areas include:

• Development of modified-release, high-potency, and fixed-dose combination oral solid dosage formulations.
• Expansion of USFDA-, EU GMP-, and WHO-GMP-compliant manufacturing capacity to strengthen domestic and export market presence.
• Investment in continuous manufacturing, process automation, Quality-by-Design (QbD), and digital manufacturing to improve efficiency and regulatory compliance.
• Strengthening CDMO partnerships, complex generic portfolios, and contract manufacturing capabilities to expand global market reach.

Market Report Scope

India Oral Solid Dosage Pharmaceutical Formulation Market Report Coverage

Analyst Opinion (Expert Opinion)

• In the coming years, India oral solid dosage pharmaceutical formulation market is expected to remain robust, driven by the country's leadership in generic drug manufacturing, increasing adoption of advanced oral drug delivery technologies, and expanding pharmaceutical exports to regulated markets. Rising demand for affordable therapies, coupled with continuous investments in formulation innovation, automation, and regulatory compliance, will strengthen India's position as a global hub for oral solid dosage manufacturing. The transition toward complex generics, modified-release formulations, and patient-centric dosage forms is expected to redefine the competitive landscape over the coming years.
• Most opportunities can be foreseen within modified-release and high-potency oral solid dosage formulations for cardiovascular diseases, diabetes, oncology, and central nervous system (CNS) disorders, particularly for the U.S., Europe, and other regulated export markets, where demand for complex generics and value-added formulations continues to increase following patent expirations. Domestic opportunities are also expected to expand with the rising burden of chronic diseases and increasing healthcare accessibility.
• To strengthen their competitive position, market players should prioritize investments in advanced formulation research, Quality-by-Design (QbD), continuous manufacturing, and digital manufacturing technologies while strengthening U.S. FDA-, EU GMP-, and WHO-GMP-compliant production capabilities. Expanding CDMO services, accelerating regulatory approvals, and developing differentiated products such as fixed-dose combinations, orally disintegrating tablets (ODTs), and modified-release formulations will be critical for enhancing global competitiveness and sustaining long-term market growth.

Market Segmentation

• Dosage Form Insights (Revenue, USD Mn, 2021 - 2033)
  • Tablets
  • Capsules
• Drug Class Insights (Revenue, USD Mn, 2021 - 2033)
  • Anticoagulants
  • Antiemetic
  • Anti-Infective
  • Antibiotics
  • Muscle Relaxant
  • Opioid
  • Others
• Application Insights (Revenue, USD Mn, 2021 - 2033)
  • Cardiovascular Diseases
  • Orthopedic
  • Gastroenterology
  • Diabetes
  • Neurology
  • Nephrology
  • Oncology
  • Infectious Diseases
  • Others
• Distribution Channel Insights (Revenue, USD Mn, 2021 - 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Key Players Insights
  • Sun Pharmaceutical Industries Limited
  • Cipla Limited
  • Reddy's Laboratories Limited
  • Lupin Limited
  • Torrent Pharmaceuticals Limited
  • Zydus Lifesciences Limited
  • Alkem Laboratories Limited
  • Aurobindo Pharma Limited
  • Mankind Pharma Limited
  • Glenmark Pharmaceuticals Limited

Sources

Primary Research Interviews

• Pharmaceutical formulation scientists specializing in oral solid dosage (OSD) development
• Manufacturing heads from tablet and capsule manufacturing facilities
• Regulatory affairs professionals specializing in CDSCO, USFDA, and EU GMP compliance
• Quality assurance (QA) and quality control (QC) experts in oral solid dosage manufacturing
• CDMO/CMO executives focusing on oral solid dosage formulations
• Hospital pharmacists and procurement managers
• Pharmaceutical supply chain and distribution specialists

Stakeholders

• Oral Solid Dosage Pharmaceutical Manufacturers (e.g., Sun Pharmaceutical Industries Limited, Cipla Limited, Dr. Reddy's Laboratories Limited)
• Contract Development and Manufacturing Organizations (CDMOs)
• Active Pharmaceutical Ingredient (API) Manufacturers
• Pharmaceutical Excipient Suppliers
• Pharmaceutical Packaging Companies
• Pharmaceutical Distributors & Wholesalers
• End-use Sectors
  • Hospitals
  • Retail Pharmacies
  • Government Healthcare Institutions
  • Specialty Clinics
  • Export Markets
• Regulatory & Health Bodies
  •  Central Drugs Standard Control Organization (CDSCO)
  • Department of Pharmaceuticals (DoP), Ministry of Chemicals & Fertilizers
  • National Pharmaceutical Pricing Authority (NPPA)
  • Indian Pharmacopoeia Commission (IPC)
  • Food and Drug Administration (FDA), Maharashtra
  • Pharmaceuticals Export Promotion Council of India (Pharmexcil)
  • World Health Organization (WHO) – Good Manufacturing Practices (GMP)
  • U.S. Food and Drug Administration (USFDA)

Databases

• CDSCO SUGAM Portal
• CDSCO New Drugs & Clinical Trials Database
• Indian Pharmacopoeia (IP) Online Portal
• National Pharmaceutical Pricing Authority (NPPA) Price Database
• Pharmexcil Export Statistics Database
• Clinical Trials Registry–India (CTRI)
• Pharmaceuticals Export Data (DGCI&S)

Journals

• International Journal of Pharmaceutics
• AAPS PharmSciTech
• Journal of Pharmaceutical Sciences
• European Journal of Pharmaceutics and Biopharmaceutics
• Drug Development and Industrial Pharmacy

Associations

• Indian Drug Manufacturers' Association (IDMA)
• Organisation of Pharmaceutical Producers of India (OPPI)
• Indian Pharmaceutical Alliance (IPA)
• Bulk Drug Manufacturers Association (BDMA)
• Confederation of Indian Industry (CII) – Pharmaceuticals Committee

Public Domain Sources

• Central Drugs Standard Control Organization (CDSCO)
• Department of Pharmaceuticals (DoP)
• National Pharmaceutical Pricing Authority (NPPA)
• Indian Pharmacopoeia Commission (IPC)
• Ministry of Chemicals & Fertilizers
• Pharmaceuticals Export Promotion Council of India (Pharmexcil)
• World Health Organization (WHO)

Proprietary Elements

• CMI Data Analytics Tool, Proprietary CMI Existing Repository of information for last 10 years.